Endothelial nitric oxide synthetase, methylenetetrahydrofolate reductase polymorphisms, and cardiovascular complications in Tunisian patients with nondiabetic renal disease.

[1]  Fu-you Liu,et al.  Association of angiotensin-converting enzyme and endothelial Nitric Oxide synthase gene polymorphisms with vascular disease in ESRD patients in a Chinese population , 2008, Molecular and Cellular Biochemistry.

[2]  É. Counil,et al.  Trends of incident dialysis patients in Tunisia between 1992 and 2001. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  H. Vannucchi,et al.  Hyperhomocysteinemia and polymorphisms of the methylenetetrahydrofolate gene in hemodialysis and peritoneal dialysis patients. , 2007, Molecular nutrition & food research.

[4]  Katrin Uhlig,et al.  Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy: a meta-analysis , 2007, Journal of Human Genetics.

[5]  F. Trivin,et al.  Hyperhomocysteinaemia, methylenetetrahydrofolate reductase polymorphism and risk of coronary artery disease , 2006, Annals of clinical biochemistry.

[6]  E. Abderrahim,et al.  [Epidemiology of glomerular diseases in Tunisia from 1975 to 2005. Influence of changes in healthcare and society]. , 2006, Bulletin de l'Academie nationale de medecine.

[7]  P. Savage.  Tumour markers in cancers of unknown primary: a clinical perspective , 2006, Annals of clinical biochemistry.

[8]  M. Margaglione,et al.  The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: results of a multicentre prospective study. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  Chul-woo Yang,et al.  Relations between eNOS Glu298Asp polymorphism and progression of diabetic nephropathy. , 2004, Diabetes research and clinical practice.

[10]  B. Kone.  Nitric oxide synthesis in the kidney: isoforms, biosynthesis, and functions in health. , 2004, Seminars in nephrology.

[11]  N. Yorioka,et al.  Association between ENOS gene polymorphism and cardiovascular events in nondiabetic hemodialysis patients: a prospective study. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  J. Werba,et al.  Hyperhomocysteinemia induces renal hemodynamic dysfunction: is nitric oxide involved? , 2003, Journal of the American Society of Nephrology : JASN.

[13]  Olaf Stanger,et al.  Interactions of Homocysteine, Nitric Oxide, Folate and Radicals in the Progressively Damaged Endothelium , 2003, Clinical chemistry and laboratory medicine.

[14]  R. Henning,et al.  Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rat. , 2002, Journal of the American Society of Nephrology : JASN.

[15]  Petra Verhoef,et al.  MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. , 2002, JAMA.

[16]  K. Tokunaga,et al.  Association of eNOS Glu298Asp Polymorphism With End-Stage Renal Disease , 2002, Hypertension.

[17]  P. Stenvinkel,et al.  Molecular genetics in renal medicine: what can we hope to achieve? , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  K. Khiari,et al.  Renal replacement therapy for diabetic end-stage renal disease. Experience of a Tunisian hospital centre. , 2001, Diabetes & metabolism.

[19]  J. Zehnder,et al.  An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. , 2001, Kidney international.

[20]  S. Kikuchi,et al.  Association of a missense Glu298Asp mutation of the endothelial nitric oxide synthase gene with end stage renal disease. , 2000, Clinical chemistry.

[21]  D. Moczulski,et al.  Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. , 2000, Kidney international.

[22]  W. Hörl,et al.  Effect of MTHFR 1298A-->C and MTHFR 677C-->T genotypes on total homocysteine, folate, and vitamin B(12) plasma concentrations in kdiney graft recipients. , 2000, Journal of the American Society of Nephrology : JASN.

[23]  C. Baylis,et al.  Total nitric oxide production is low in patients with chronic renal disease. , 2000, Kidney international.

[24]  D. Wilcken,et al.  Homocysteine and cardiovascular disease: cause or effect? , 2000, The American journal of clinical nutrition.

[25]  F. Gejyo,et al.  The C677T methylenetetrahydrofolate reductase gene mutation in hemodialysis patients. , 2000, Journal of the American Society of Nephrology : JASN.

[26]  Mohamed,et al.  Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. , 2000, Kidney international.

[27]  J. Moss,et al.  Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Kikuchi,et al.  Endothelial nitric oxide synthase gene polymorphism in intron 4 affects the progression of renal failure in non-diabetic renal diseases. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  A. Hingorani,et al.  A common variant of the endothelial nitric oxide synthase (Glu298-->Asp) is a major risk factor for coronary artery disease in the UK. , 1999, Circulation.

[30]  M. Hijmering,et al.  Nitric oxide production is reduced in patients with chronic renal failure. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[31]  C. Baylis,et al.  Chronic nitric oxide inhibition model six years on. , 1998, Hypertension.

[32]  H. Itoh,et al.  Endothelial nitric oxide synthase gene is positively associated with essential hypertension. , 1998, Hypertension.

[33]  R. Rozen,et al.  A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. , 1998, Molecular genetics and metabolism.

[34]  Y. Kawaguchi,et al.  High Accumulation of Endothelial Nitric Oxide Synthase (ecNOS):A Gene Polymorphism in Patients with End-Stage Renal Disease , 1998, Nephron.

[35]  W. Hörl,et al.  Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. , 1998, Kidney international.

[36]  P. Ueland,et al.  Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. , 1997, Kidney international.

[37]  W. Hörl,et al.  Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. , 1997, Kidney international.

[38]  I. Rosenberg,et al.  Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. , 1996, Atherosclerosis.

[39]  R. Zatz,et al.  Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. , 1992, Hypertension.

[40]  A. Deng,et al.  Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. , 1992, The Journal of clinical investigation.

[41]  R. Zatz,et al.  Effects of acute nitric oxide inhibition on rat glomerular microcirculation. , 1991, The American journal of physiology.

[42]  P. Czernichow,et al.  HLA-DQB 1 codon 57 and genetic susceptibility to Type 1 (insulin-dependent) diabetes mellitus in French children , 1990, Diabetologia.

[43]  S. Moncada,et al.  Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses. , 1990, The American journal of physiology.

[44]  B. Thornhill,et al.  Lack of endothelial nitric-oxide synthase leads to progressive focal renal injury. , 2007, The American journal of pathology.

[45]  M. Vaxillaire,et al.  MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. , 2007, Diabetes research and clinical practice.

[46]  Natalia Mendelev,et al.  Chronic NOS inhibition actuates endothelial-mesenchymal transformation. , 2007, American journal of physiology. Heart and circulatory physiology.

[47]  F. Trivin,et al.  Hyperhomocysteinemia, endothelial nitric oxide synthase polymorphism, and risk of coronary artery disease. , 2006, Clinical chemistry.

[48]  Ying Wang,et al.  Association of ecNOS gene polymorphisms with end stage renal diseases , 2004, Molecular and Cellular Biochemistry.

[49]  I. Rosenberg,et al.  Serum cystatin C as a determinant of fasting total homocysteine levels in renal transplant recipients with a normal serum creatinine. , 1999, Journal of the American Society of Nephrology : JASN.

[50]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[51]  A. Szabó,et al.  J Am Soc Nephrol 14: 2526–2533, 2003 Protection of Wistar Furth Rats from Chronic Renal Disease Is Associated with Maintained Renal Nitric Oxide Synthase , 2022 .